Why the study?
Does transgenic expression of mIGF-1 improve recovery of heart functionality in post-infarct mice?
Does transgenic expression of mIGF-1 improve recovery of heart functionality in post-infarct mice?
Local expression of mIGF-1 in the post-infarct mouse heart restores cardiac function through alternative signaling pathways, providing a potential mechanistic basis for novel heart failure therapies.
Preclinical mIGF-1 findings in mice warrant further study; leaves open translation to human post-MI therapies.
The injured mammalian heart is particularly susceptible to tissue deterioration, scarring, and loss of contractile function in response to trauma or sustained disease. We tested the ability of a locally acting insulin-like growth factor-1 isoform (mIGF-1) to recover heart functionality, expressing the transgene in the mouse myocardium to exclude endocrine effects on other tissues. supplemental mIGF-1 expression did not perturb normal cardiac growth and physiology. Restoration of cardiac function in post-infarct mIGF-1 transgenic mice was facilitated by modulation of the inflammatory response and increased antiapoptotic signaling. mIGF-1 ventricular tissue exhibited increased proliferative activity several weeks after injury. The canonical signaling pathway involving Akt, mTOR, and p70S6 kinase was not induced in mIGF-1 hearts, which instead activated alternate PDK1 and SGK1 signaling intermediates. The robust response achieved with the mIGF-1 isoform provides a mechanistic basis for clinically feasible therapeutic strategies for improving the outcome of heart disease.
No takes yet. Share an insight, caveat, or question.
Santini et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: